Compugen Ltd stock is traded at $2.09, with a volume of 211,132. It is up 0.00% in the last 24 hours and up +0.97% over the past month. Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Previous Close:
$2.09
Open:
$2.09
24h Volume:
211,132
Relative Volume:
0.97
Market Cap:
$197.98M
Revenue:
$72.66M
Net Income/Loss:
$34.86M
P/E Ratio:
5.71
EPS:
$0.366
Net Cash Flow:
-$62.91M
1W Performance:
+8.85%
1M Performance:
+0.97%
6M Performance:
-26.15%
1Y Performance:
+24.40%
1-Day Range:
$2.07$2.12
1-Week Range:
$1.88$2.15
52-Week Range:
$1.43$3.24
Compugen Ltd Stock (CGEN) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS